復星醫藥(02196)創新藥FXS0887獲批臨床 擬治療晚期惡性實體瘤 X
04/12/2025 18:23
<匯港通訊>    復星醫藥(02196)發稿，指近日控股子公司復星醫藥產業，收到國家藥監局關於同意FXS887片(FXS0887)對晚期惡性實體瘤開展臨床試驗的批准。復星醫藥產業擬於條件具備後於中國境內開展FXS0887的I期臨床試驗。

截至目前的臨床前研究顯示，該新藥在多種類型腫瘤模型中表現出良好的抗腫瘤活性，脫靶風險較小，安全性良好。截至2025年10月，復星醫藥現階段針對FXS0887的累計研發投入約0.44億元人民幣（未經審計）。截至目前，全球範圍內尚無同靶點產品單藥或聯合治療方案獲批上市。

 (SY)

(C) Copyright by Infocast Ltd. All Rights Reserved.

Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.